Nemonoxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nemonoxacin
Accession Number
DB06600
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
tg-873870
Categories
UNII
P94L0PVO94
CAS number
378746-64-6
Weight
Average: 371.437
Monoisotopic: 371.184506297
Chemical Formula
C20H25N3O4
InChI Key
AVPQPGFLVZTJOR-RYUDHWBXSA-N
InChI
InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
IUPAC Name
7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N1C[[email protected]@H](C)C[[email protected]](N)C1)C1CC1

Pharmacology

Indication

Investigated for use/treatment in bacterial infection and pneumonia.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Nemonoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nemonoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Nemonoxacin.Experimental, Illicit
AceclofenacAceclofenac may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Nemonoxacin.Approved, Experimental, Investigational
AcenocoumarolNemonoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Nemonoxacin.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Nemonoxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nemonoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nemonoxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Nemonoxacin.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Nemonoxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nemonoxacin.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Nemonoxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Nemonoxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Nemonoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Nemonoxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Nemonoxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Nemonoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nemonoxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Nemonoxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Nemonoxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Nemonoxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nemonoxacin.Approved, Vet Approved
BevoniumBevonium may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Nemonoxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Nemonoxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Nemonoxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium laevulate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Nemonoxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Nemonoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Nemonoxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Nemonoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Nemonoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nemonoxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Nemonoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nemonoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Nemonoxacin.Approved
ClorindioneNemonoxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Nemonoxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Nemonoxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nemonoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Nemonoxacin.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Nemonoxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nemonoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Nemonoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Nemonoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nemonoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Nemonoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
DicoumarolNemonoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Nemonoxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Nemonoxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Nemonoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Nemonoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Nemonoxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Nemonoxacin.Approved
DiphenadioneNemonoxacin may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamDroxicam may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
DuvelisibDuvelisib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
E-6201E-6201 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Nemonoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Nemonoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Nemonoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Nemonoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Nemonoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Ethyl biscoumacetateNemonoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Nemonoxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Nemonoxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Nemonoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Nemonoxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Nemonoxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Nemonoxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Nemonoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nemonoxacin.Approved
FluindioneNemonoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nemonoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Nemonoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Nemonoxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nemonoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Nemonoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Nemonoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nemonoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Nemonoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Nemonoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nemonoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nemonoxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Nemonoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Nemonoxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the neuroexcitatory activities of Nemonoxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Nemonoxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Nemonoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nemonoxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Nemonoxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Nemonoxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
IsoxicamIsoxicam may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Nemonoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Nemonoxacin.Approved
Lanthanum carbonateThe serum concentration of Nemonoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Nemonoxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Nemonoxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Nemonoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateMagnesium salicylate may increase the neuroexcitatory activities of Nemonoxacin.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Nemonoxacin.Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Nemonoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Nemonoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Nemonoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Nemonoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Nemonoxacin.Investigational, Withdrawn
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nemonoxacin.Approved, Vet Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Nemonoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nemonoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Nemonoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Nemonoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Nemonoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Nemonoxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Nemonoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Nemonoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Nemonoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Nemonoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Nemonoxacin.Vet Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Nemonoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Nemonoxacin.Approved, Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nemonoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Nemonoxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
PhenindioneNemonoxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNemonoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Nemonoxacin.Experimental
PranoprofenPranoprofen may increase the neuroexcitatory activities of Nemonoxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Nemonoxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Nemonoxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nemonoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nemonoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Nemonoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nemonoxacin.Experimental, Investigational
ProbenecidThe serum concentration of Nemonoxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Nemonoxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
QuinaprilThe serum concentration of Nemonoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Nemonoxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Nemonoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational, Withdrawn
SalicylamideSalicylamide may increase the neuroexcitatory activities of Nemonoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Nemonoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Nemonoxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Nemonoxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Nemonoxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Nemonoxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
Strontium ranelateThe serum concentration of Nemonoxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Nemonoxacin can be decreased when it is combined with Sucralfate.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Nemonoxacin.Approved
SulindacSulindac may increase the neuroexcitatory activities of Nemonoxacin.Approved
SuprofenSuprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Nemonoxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Nemonoxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Nemonoxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Nemonoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Nemonoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Nemonoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Nemonoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
TioclomarolNemonoxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Nemonoxacin.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Nemonoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Nemonoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nemonoxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Nemonoxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Nemonoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Nemonoxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nemonoxacin.Approved
WarfarinNemonoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Nemonoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Nemonoxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
10166207
ChEBI
136053
ChEMBL
CHEMBL1213456
ATC Codes
J01MB08 — Nemonoxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers2
1Not Yet RecruitingNot AvailableRenal Function Abnormal1
1RecruitingNot AvailableLiver Dysfunction1
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)2
2CompletedTreatmentDiabetic Foot Infections1
2CompletedTreatmentPneumonia1
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
3CompletedTreatmentPneumonia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.453 mg/mLALOGPS
logP0.32ALOGPS
logP-0.44ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)5.73ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area96.1 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity103.06 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Methoxyanilines / Dialkylarylamines / Anisoles / Alkyl aryl ethers / Aminopiperidines / Vinylogous amides
show 9 more
Substituents
Quinoline-3-carboxylic acid / Aminoquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Methoxyaniline / Anisole / Dialkylarylamine / Tertiary aliphatic/aromatic amine
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on March 19, 2008 10:39 / Updated on January 05, 2018 16:04